OverviewSuggest Edit

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, and clinical development. 
TypePublic
Founded2009
HQWestminster, US
Websitearcabio.com

Latest Updates

Employees (est.) (Dec 2019)9(-40%)
Revenue (FY, 2019)$0
Share Price (Sept 2020)$4.2 (-9%)
Cybersecurity ratingAMore

Key People/Management at ARCA biopharma

Michael R. Bristow

Michael R. Bristow

President & Chief Executive Officer
Thomas A. Keuer

Thomas A. Keuer

Chief Operating Officer
Brian Selby

Brian Selby

Vice President Finance & Chief Accounting Officer
Christopher D. Ozeroff

Christopher D. Ozeroff

Senior Vice President & General Counsel
Robert E. Conway

Robert E. Conway

Chairman
Linda Grais

Linda Grais

Director
Show more

ARCA biopharma Office Locations

ARCA biopharma has offices in Westminster and Aurora
Westminster, US (HQ)
11080 Circle Point Rd #140
Aurora, US
12635 E Montview Blvd
Westminster, US
11080 Circle Point Rd #140
Show all (3)

ARCA biopharma Financials and Metrics

ARCA biopharma Revenue

USD

Net income (Q2, 2020)

(1.3m)

EBIT (Q2, 2020)

(1.3m)

Market capitalization (23-Sept-2020)

24.7m

Closing stock price (23-Sept-2020)

4.2

Cash (30-Jun-2020)

11.0m

EV

38.6m
ARCA biopharma's current market capitalization is $24.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

5.0m3.2m4.0m4.1m4.4m4.3m4.6m3.9m4.0m

R&D expense

2.3m1.1m2.9m5.6m7.1m12.3m14.1m4.2m1.8m

Operating expense total

7.4m4.3m6.9m9.7m11.5m16.6m18.7m8.1m5.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

General and administrative expense

1.2m1.3m984.0k823.0k889.0k952.0k1.0m1.1m1.0m950.0k1.0m972.0k1.1m1.1m1.0m992.0k1.1m1.1m987.0k1.1m1.0m922.0k1.1m1.1m900.0k975.0k938.0k

R&D expense

497.0k533.0k422.0k322.0k181.0k246.0k714.0k1.3m1.4m1.3m1.7m1.7m1.7m2.6m2.9m3.7m3.2m4.5m3.5m1.7m1.2m740.0k662.0k440.0k347.0k365.0k372.0k

Operating expense total

1.7m1.8m1.4m1.1m1.1m1.2m1.7m2.4m2.4m2.3m2.7m2.7m2.8m3.7m3.9m4.7m4.4m5.6m4.5m2.8m2.2m1.7m1.8m1.5m1.2m1.3m1.3m
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

ARCA biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

ARCA biopharma Online and Social Media Presence

Embed Graph

ARCA biopharma News and Updates

ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has submitted an Investigational New Drug (IND…

ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering

WESTMINSTER, Colo., June 03, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the closing of its previously announced …

ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Feb. 18, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2…

ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Aug. 01, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 20…

Thinking about buying stock in Arca Biopharma, Cronos Group, Nio Inc., Precipio, or Square?

NEW YORK, May 2, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABIO, CRON, NIO, PRPO, and SQ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial

Steering Committee to Provide Scientific Oversight and Guidance for Pivotal Phase 3 Trial Evaluating Gencaro as Potentially the First Genetically-Targeted Treatment for Atrial Fibrillation Steering Committee to Provide Scientific Oversight and Guidance for Pivotal Phase 3 Trial Evaluating Gencaro as…
Show more

ARCA biopharma Frequently Asked Questions

  • When was ARCA biopharma founded?

    ARCA biopharma was founded in 2009.

  • Who are ARCA biopharma key executives?

    ARCA biopharma's key executives are Michael R. Bristow, Thomas A. Keuer and Brian Selby.

  • How many employees does ARCA biopharma have?

    ARCA biopharma has 9 employees.

  • Who are ARCA biopharma competitors?

    Competitors of ARCA biopharma include LogicBio Therapeutics, Sarepta Therapeutics and Intellia Therapeutics.

  • Where is ARCA biopharma headquarters?

    ARCA biopharma headquarters is located at 11080 Circle Point Rd #140, Westminster.

  • Where are ARCA biopharma offices?

    ARCA biopharma has offices in Westminster and Aurora.

  • How many offices does ARCA biopharma have?

    ARCA biopharma has 3 offices.